ArticleAnnals of surgical oncology2026
Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver Injury and Postoperative Complications.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
objectivesOxaliplatin-based neoadjuvant therapy (NAT) is increasingly being used in patients undergoing curative-intent surgery for pancreatic ductal adenocarcinoma (PDAC). Liver toxicity, notably through the development of chemotherapy-associated liver injury (CALI), has been shown in patients with colorectal liver metastases. However, its impact on postoperative complications after pancreaticoduodenectomy (PD) is not known. The study aimed to assess the hepatic changes on computed tomography (CT) imaging after oxaliplatin-based NAT and to identify markers predictive of postoperative complications. MATERIALS AND
methodsCT scans were retrospectively analyzed before and after oxaliplatin-based NAT of consecutive patients undergoing PD for PDAC between 2017 and 2020. The appearance of qualitative and quantitative features of CALI, such as liver attenuation, liver surface nodularity, hepatic and splenic volumetry, liver enhancement patterns, and features of portal hypertension, were derived from CT images, and their association with postoperative complications were analyzed.
resultsA total of 122 patients were analyzed (58 women; median age, 65 years [IQR,57-69]). Most patients received FOLFIRINOX protocol (n = 107, 87.7%). After chemotherapy, the splenic volume, heterogeneity of hepatic parenchymal enhancement, and portosystemic shunts significantly increased (p < 0.001). Preoperative low liver attenuation on unenhanced CT and heterogeneity of the liver parenchyma on contrast-enhanced CT were significantly associated with severe postoperative complications (p < 0.001). Liver attenuation value on unenhanced CT was inversely correlated with the Comprehensive Complication Index score (correlation coefficient -0.329, p < 0.001).
conclusionsAfter oxaliplatin-based NAT for pancreatic ductal adenocarcinoma, imaging-based signs of CALI were associated with severe complications after pancreaticoduodenectomy.
Indexed as
Identifiers
41922862What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.